S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

$32.86
+0.73 (+2.27%)
(As of 03/27/2024 ET)
Today's Range
$31.76
$33.00
50-Day Range
$31.72
$42.99
52-Week Range
$15.32
$43.81
Volume
867,781 shs
Average Volume
442,240 shs
Market Capitalization
$884.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.71

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.6% Upside
$57.71 Price Target
Short Interest
Bearish
17.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Arcturus Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$910,434 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.42) to $5.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

540th out of 939 stocks

Pharmaceutical Preparations Industry

253rd out of 430 stocks

ARCT stock logo

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

ARCT Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
ARCT Apr 2024 30.000 call
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Recap: Arcturus Therapeutics Q4 Earnings
ARCT Sep 2024 30.000 put
Earnings Preview: Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc (ARCT)
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.71
High Stock Price Target
$90.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+75.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-29,730,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$169.93 million
Book Value
$10.42 per share

Miscellaneous

Free Float
23,201,000
Market Cap
$884.59 million
Optionable
Optionable
Beta
2.64
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 52)
    Founder, President, CEO & Director
    Comp: $1.13M
  • Mr. Andrew H. Sassine MBA (Age 60)
    CFO & Director
    Comp: $826.88k
  • Ms. Neda Safarzadeh
    Vice President and Head of IR/PR & Marketing
  • Mr. Lance Kurata
    Chief Legal Officer
  • Ms. Natash O. Bowman
    Chief Human Resources Officer
  • Mr. Kevin T. Skol
    Chief Business Officer
  • Dr. Juergen Froehlich FCPh (Age 68)
    M.D., MBA, Chief Medical Officer
  • Dr. Igor Smolenov M.D.
    Ph.D., Chief Development Officer

ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price target for 2024?

7 brokerages have issued 12 month price targets for Arcturus Therapeutics' shares. Their ARCT share price targets range from $36.00 to $90.00. On average, they predict the company's stock price to reach $57.71 in the next twelve months. This suggests a possible upside of 75.6% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 at the beginning of the year. Since then, ARCT stock has increased by 4.2% and is now trading at $32.86.
View the best growth stocks for 2024 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company earned $2.44 million during the quarter, compared to analysts' expectations of $26.70 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 18.22% and a negative net margin of 15.65%. During the same period in the prior year, the company posted ($0.92) earnings per share.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%) and Dimensional Fund Advisors LP (4.08%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners